Can vagus nerve stimulation treat chronic depression?

What is VNS and how does it work for depression?

Vagus nerve stimulation (VNS) is a neuromodulation therapy that involves implanting a small device, similar to a pacemaker, under the skin in the chest. This device is connected to a wire that wraps around the vagus nerve in the neck, delivering mild, intermittent electrical pulses to the brain. The vagus nerve is a major information highway connecting the brain to the body, and stimulating it can influence mood-regulating circuits. This approach is not a quick fix but a long-term, adjunctive treatment—meaning it is used alongside, not instead of, other treatments like medication and therapy [4][8].

The idea that VNS could treat depression emerged from its use in epilepsy, where doctors noticed that patients' moods often improved alongside seizure control [1][8]. This led to clinical trials, and VNS is now an FDA-approved treatment for treatment-resistant depression (TRD) [8]. The therapy is thought to work by promoting neuroplasticity—the brain's ability to form new connections—and by reducing inflammation, which is increasingly recognized as a factor in a subtype of depression [3][6][7].

Does it really work? The evidence for effectiveness.

The evidence from the studies here strongly supports VNS as an effective treatment for chronic, treatment-resistant depression, especially over the long term. A key finding comes from the large, randomized RECOVER trial, which showed that patients with a history of electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)—who typically have a very poor prognosis—experienced significantly greater benefit from active VNS compared to a sham (inactive) device [2]. This is a powerful result because it identifies the very patients who are hardest to treat as the ones who may benefit most.

Other studies reinforce this. A case series of 12 patients with severe, difficult-to-treat depression found a 41% average reduction in depression severity scores (measured by the MADRS scale) after 12 months of VNS, and some patients were able to stop maintenance ECT or esketamine treatments [4]. A preliminary study of 7 Chinese patients reported that after 9 months, 85.7% had responded to treatment and 57.1% were in remission [5]. Most strikingly, a long-term follow-up of 5 patients found that 3 maintained a clinical response for over 10 years, suggesting VNS can produce durable, lasting change [6]. Across these studies, the pattern is clear: VNS is not a miracle cure, but for a substantial portion of people with otherwise untreatable depression, it can be transformative.

What are the catch? Side effects and who it's for.

VNS is not a first-line treatment. It is reserved for people with 'treatment-resistant depression' (TRD), meaning they have not responded to multiple adequate trials of medication, therapy, and often more intensive treatments like ECT or TMS [2][4][5]. The therapy requires a surgical procedure to implant the device, which carries its own risks, though the studies here report it is generally safe and well-tolerated [9].

The most common side effects are related to the stimulation itself and are usually mild. In epilepsy studies, the most frequent side effects were hoarseness or voice alteration (affecting about 2 in 3 patients in one depression study [5]), cough, and shortness of breath [1][5]. These effects often lessen over time as the device is adjusted. More serious complications, like vocal cord paresis (weakness), are rare and typically resolve [9]. One patient in a long-term study experienced a hypomanic episode after discontinuing their medication, highlighting that VNS is an adjunctive therapy and should not replace other treatments without medical supervision [6].

It is also important to note that VNS is not for everyone. The RECOVER trial found that patients with a comorbid anxiety disorder had a better overall prognosis but showed less additional benefit from VNS compared to those without anxiety [2]. This suggests that VNS may be particularly well-suited for patients whose depression is the primary, dominant problem, especially if they have not responded to ECT or TMS.

About These Sources

This answer is built on 9 peer-reviewed studies — published from 2022 to 2025, 2 from 2024 or later, 6 in Q1 journals, collectively cited 205 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 52 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions